Literature DB >> 20371286

Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.

Handoko Adi1, Paul M Young, Hak-Kim Chan, Helen Agus, Daniela Traini.   

Abstract

The aim of this study was to assess the potential of delivering a combination therapy, containing mannitol (a sugar alcohol with osmotic characteristics), and ciprofloxacin hydrochloride (an antibacterial fluoroquinolone), as a dry powder inhaler (DPI) formulation for inhalation. Single and combination powders were produced by spray drying ciprofloxacin and mannitol, from aqueous solution, at different ratios and under controlled conditions, as to obtain similar particle size distributions. Each formulation was characterised using laser diffraction, scanning electron microscopy, differential scanning calorimetry, dynamic vapour sorption, X-ray powder diffraction, and colloidal force microscopy. The in vitro aerosol performance of each formulation was studied using an Aerolizer DPI device and a multi-stage liquid impinger (analysed using high performance liquid chromatography). In addition, a disk diffusion test was performed to assess the in vitro antimicrobial activity of each formulation and starting materials. All formulations had similar particle size distributions, however, the morphology, thermal properties and moisture sorption was dependent on the relative percentages of each component. In general, the combination formulation containing 50% (w/w) mannitol appeared to have the best aerosol performance, good stability and lowest particle cohesion (as measured by colloid probe microscopy). Furthermore, of the formulations tested, mannitol did not appear to alter the effectiveness of the ciprofloxacin antimicrobial activity to Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pyogenes. The combination of co-spray-dried mannitol and ciprofloxacin from a DPI is an attractive approach to promote mucous clearance in the respiratory tract while simultaneously treating local chronic infection, such as chronic obstructive pulmonary disease and cystic fibrosis. Crown Copyright 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371286     DOI: 10.1016/j.ejps.2010.03.020

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  19 in total

1.  Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.

Authors:  Philip Chi Lip Kwok; Amolnat Tunsirikongkon; William Glover; Hak-Kim Chan
Journal:  Pharm Res       Date:  2010-12-07       Impact factor: 4.200

Review 2.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

Review 3.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

4.  Effects of Moisture-Induced Crystallization on the Aerosol Performance of Spray Dried Amorphous Ciprofloxacin Powder Formulations.

Authors:  Nivedita Shetty; Lingfei Zeng; Sharad Mangal; Haichen Nie; Matthew R Rowles; Rui Guo; Youngwoo Han; Joon Hyeong Park; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-01-02       Impact factor: 4.200

5.  Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.

Authors:  Nivedita Shetty; Heejun Park; Dmitry Zemlyanov; Sharad Mangal; Sonal Bhujbal; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-04-18       Impact factor: 5.875

6.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

7.  Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases.

Authors:  Hui Xin Ong; Daniela Traini; Giulia Ballerin; Lucy Morgan; Lachlan Buddle; Santo Scalia; Paul M Young
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

Review 8.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

9.  Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device.

Authors:  Hiroko Otake; Tomoyuki Okuda; Daiki Hira; Haruyoshi Kojima; Yasuhiro Shimada; Hirozazu Okamoto
Journal:  Pharm Res       Date:  2015-12-07       Impact factor: 4.200

10.  Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model.

Authors:  Hui Xin Ong; Daniela Traini; Mary Bebawy; Paul M Young
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.